127 related articles for article (PubMed ID: 10789510)
1. Inhibition of HIV-1 infection by an intramolecular antisense peptide to T20 in gp160.
Imai M; Okada N; Okada H
Microbiol Immunol; 2000; 44(3):205-12. PubMed ID: 10789510
[TBL] [Abstract][Full Text] [Related]
2. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41.
Jiang S; Lin K; Strick N; Neurath AR
Biochem Biophys Res Commun; 1993 Sep; 195(2):533-8. PubMed ID: 8373393
[TBL] [Abstract][Full Text] [Related]
4. The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20.
Trivedi VD; Cheng SF; Wu CW; Karthikeyan R; Chen CJ; Chang DK
Protein Eng; 2003 Apr; 16(4):311-7. PubMed ID: 12736375
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.
Lawless MK; Barney S; Guthrie KI; Bucy TB; Petteway SR; Merutka G
Biochemistry; 1996 Oct; 35(42):13697-708. PubMed ID: 8885850
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
[TBL] [Abstract][Full Text] [Related]
7. Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41.
Xu W; Pu J; Su S; Hua C; Su X; Wang Q; Jiang S; Lu L
AIDS; 2019 Aug; 33(10):1545-1555. PubMed ID: 30932963
[TBL] [Abstract][Full Text] [Related]
8. The Glu143 Residue Might Play a Significant Role in T20 Peptide Binding to HIV-1 Receptor gp41: An In Silico Study.
Alaofi AL
Molecules; 2022 Jun; 27(12):. PubMed ID: 35745059
[TBL] [Abstract][Full Text] [Related]
9. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
10. Depletion in antibodies targeted to the HR2 region of HIV-1 glycoprotein gp41 in sera of HIV-1-seropositive patients treated with T20.
Vincent N; Tardy JC; Livrozet JM; Lucht F; Frésard A; Genin C; Malvoisin E
J Acquir Immune Defic Syndr; 2005 Mar; 38(3):254-62. PubMed ID: 15735441
[TBL] [Abstract][Full Text] [Related]
11. Membrane-anchored peptide inhibits human immunodeficiency virus entry.
Hildinger M; Dittmar MT; Schult-Dietrich P; Fehse B; Schnierle BS; Thaler S; Stiegler G; Welker R; von Laer D
J Virol; 2001 Mar; 75(6):3038-42. PubMed ID: 11222732
[TBL] [Abstract][Full Text] [Related]
12. Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.
Cai L; Pan C; Xu L; Shui Y; Liu K; Jiang S
FASEB J; 2012 Mar; 26(3):1018-26. PubMed ID: 22085645
[TBL] [Abstract][Full Text] [Related]
13. The binding mode of fusion inhibitor T20 onto HIV-1 gp41 and relevant T20-resistant mechanisms explored by computational study.
Qiu S; Yi H; Hu J; Cao Z; Wu Y; Li W
Curr HIV Res; 2012 Mar; 10(2):182-94. PubMed ID: 22339124
[TBL] [Abstract][Full Text] [Related]
14. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
[TBL] [Abstract][Full Text] [Related]
15. T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor.
Su SB; Gong WH; Gao JL; Shen WP; Grimm MC; Deng X; Murphy PM; Oppenheim JJ; Wang JM
Blood; 1999 Jun; 93(11):3885-92. PubMed ID: 10339497
[TBL] [Abstract][Full Text] [Related]
16. Mutation L33M in the HR1 region of HIV-1 gp41 may play a role in T20 resistance.
Chong H; Xu S; Zhang C; Nie J; Wang Y
J Clin Virol; 2009 Jul; 45(3):255-8. PubMed ID: 19487156
[TBL] [Abstract][Full Text] [Related]
17. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
18. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.
He Y; Cheng J; Lu H; Li J; Hu J; Qi Z; Liu Z; Jiang S; Dai Q
Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16332-7. PubMed ID: 18852475
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments.
Imai M; Baranyi L; Okada N; Okada H
Biochem Biophys Res Commun; 2007 Feb; 353(4):851-6. PubMed ID: 17210123
[TBL] [Abstract][Full Text] [Related]
20. C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread.
Medinas RJ; Lambert DM; Tompkins WA
J Virol; 2002 Sep; 76(18):9079-86. PubMed ID: 12186891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
